PatientsVille.com Logo


Lenalidomide Medical Research Studies

Up-to-date List of Lenalidomide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lenalidomide Medical Research Studies

Rank Status Study
1 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: Lenalidomide, endoxan, prednisone
Outcome Measures: Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT);   phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT);   phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
2 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
Outcome Measures: Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL);   Adverse Events;   Complete response rate;   Overall response rate;   Duration of response;   Duration of complete response;   Time to the next anti-lymphoma treatment;   Time to treatment failure;   Time to histological transformation
3 Recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination with azacitidine
Outcome Measures: Survival;   Remission Rate;   Remission Duration;   Cytogenetic Complete Remission Rate;   Overall Response Rate;   Progression-free survival;   Event-free survival;   Relapse-free survival;   30-day treatment-related mortality;   Safety and Tolerability
4 Recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
Outcome Measures: Type, frequency, severity and timing of adverse events and their relationship to combination therapy with Lenalidomide plus dexamethasone.;   Duration of M-Protein response during combination therapy with Lenalidomide plus dexamethasone;   Confirmed M-Protein response;   Expression of angiogenic factors, cytokines, adhesion molecules, and myeloma biomarker expression
5 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
Outcome Measures: Maximum Tolerated Dose (MTD) of Lenalidomide/Dexamethasone and All-Trans Retinoic Acid (ATRA);   Objective Response
6 Not yet recruiting Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Conditions: Multiple Myeloma;   Neoplasms;   Plasma Cells;   Paraproteinemias;   Blood Protein Disorders;   Hematologic Diseases;   Therapeutic Uses
Intervention: Drug: Lenalidomide
Outcome Measures: Progression free survival (PFS);   Response Rate;   Time to progression (TTP);   Overall survival (OS);   Safety
7 Recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
Outcome Measures: Maximum Tolerated Dose (MTD) of Ipilimumab in Combination With Lenalidomide;   Dose-Limiting Toxicities (DLT) of Ipilimumab in Combination With Lenalidomide
8 Recruiting Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide; Chlorambucil
Outcome Measures: PhI: MTD of Lenalidomide given in combination with Chlorambucil.;   PhII: To evaluate the overall response rate of an induction therapy consisting of Lenalidomide given at the MTD in combination with Chlorambucil.;   Lenalidomide and chlorambucil induction therapy in terms of safety;;   Post-remissional phase with Lenalidomide in terms of safety;   Lenalidomide maintenance efficacy in terms of CR rate.;   Progression free survival estimation according to the post-remissional approach. Lenalidomide maintenance therapy or clinical observation.;   Association between the response and the baseline biologic factors (IgVH, p53, FISH, ZAP-70, CD38);   Progression free survival estimation according to the baseline biologic factors starting from the date of first dose of study drug in the induction phase.;   Time to a new CLL treatment or death estimation.;   Overall survival estimation
9 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: Lenalidomide maintenance;   Drug: Lenalidomide plus vorinostat maintenance
Outcome Measures: Overall survival;   Progression-free survival;   Response;   Toxicity
10 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone
Outcome Measures: Phase I: Dose limiting toxicity;   Phase II: Overall response;   Phase I/II: Frequency and percent of occurrence of adverse events during each cycle of treatment, and within patients;   Phase I/II: Disease control, i.e. no progression at 16 weeks after start of trial therapy;   Phase I/II: Duration of response;   Phase I/II: Overall survival;   Phase I/II: Progression free survival;   Phase I/II: Time to progression;   Phase I: Overall response
11 Recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: Lenalidomide
Outcome Measures: Determine the overall response rate (ORR), including complete responses (CR) and partial responses (PR), with combined Lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin's lymphoma.;   Assess the safety and tolerability of combined Lenalidomide and panobinostat in patients with previously treated Hodgkin's lymphoma.;   Determine progression-free survival in patients with previously treated Hodgkin's lymphoma receiving combined Lenalidomide and panobinostat
12 Not yet recruiting Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Condition: Multiple Myeloma
Intervention: Drug: Revlimid (Lenalidomide)
Outcome Measures: Progression Free Survival (PFS);   Response Rates;   Overall Survival (OS);   Time to Response (TTR) and Duration of Response (DOR);   Duration of Treatment with Revlimid;   Safety Profile of Revlimid
13 Recruiting Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
Outcome Measures: overall response rate (ORR);   toxicity
14 Not yet recruiting Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission
Condition: Leukemia
Intervention: Drug: Lenalidomide
Outcome Measure: Relapse-Free Survival (RFS) With Lenalidomide Maintenance Therapy
15 Recruiting Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACY-1215;   Drug: Lenalidomide;   Drug: Dexamethasone
Outcome Measures: Establish optimal dose of ACY-1215 in combination with Lenalidomide and dexamethasone;   Evaluate safety by assessing toxicities;   Determine the preliminary anti-tumor activity of ACY-1215 in combination with Lenalidomide and dexamethasone;   Area under the plasma concentration versus time curve (AUC);   Changes in acetylated tubulin and acetylated histone levels
16 Recruiting Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Outcome Measures: Complete Response;   Overall Response Rate
17 Recruiting Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Condition: Previously Untreated Symptomatic Multiple Myeloma
Interventions: Drug: Lenalidomide, Bortezomib;   Biological: autologous stem cell transplant;   Biological: allogeneic stem cell transplant
Outcome Measures: The primary efficacy endpoint for the induction phase is the rate of patients with CR at first restaging;   In the consolidation phase the primary efficacy endpoint for comparison II (response <VGPR after first ASCT) is the PFS rate;   ORR following 3 cycles of induction treatment (VRD vs RAD);   CR and ORR at the end of the whole treatment programme;   Overall survival (OS);   Incidence, severity and relationship of SAEs;   Numbers of hospital stays and hospitalization days
18 Recruiting Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)
Conditions: Blood And Marrow Transplantation;   Leukemia;   Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ipilimumab
Outcome Measure: Toxicity Rate
19 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
Outcome Measures: Maximum Tolerated Dose (MTD) of Lenalidomide plus Obinutuzumab;   Objective Response
20 Recruiting Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
Condition: Myeloma
Interventions: Drug: Panobinostat;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Behavioral: Symptom Questionnaire
Outcome Measure: Maximum Tolerated Dose (MTD) of Panobinostat with Bortezomib, Lenalidomide, and Dexamethasone

These studies may lead to new treatments and are adding insight into Lenalidomide etiology and treatment.

A major focus of Lenalidomide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Lenalidomide